- Home
- Solutions
- By Diseases
- Congenital Ophthalmic Diseases
- Microspherophakia (MSP)
Microspherophakia (MSP) is a rare congenital eye disorder characterized by a small, spherically-shaped crystalline lens. Protheragen is committed to advancing the diagnostics and therapeutics of microspherophakia through innovative research and development services.
Description of microspherophakia which is a birth defect shows how unique its morphology is. It is where children are born with a small lens that has an increased anteroposterior diameter and reduced lens equatorial diameter. Children who suffer from this condition face extreme ocular problems; bilateral presentation has an association with subluxation of the lens, high myopia, and secondary glaucoma. The surrounding zonules and capsular tension cause the lens to stay small and spherical which increases risks of angle-closure glaucoma and corneal dysfunction. After attaining corneal endothelial dysfunction, the next step where patients face the threat of complete blindness makes early intervention crucial.
Fig.1 Decision tree for microspherophakia. (Venkataraman, P., et al., 2022)Microspherophakia diagnostics is incorporating genetic testing more with time owing to systematic associations. A number of genes including, but not limited to, FBN1, ADAMTS10, ADAMTS17, and LTBP2 have been suggested as potential causal mutations of the condition. Genetic analysis helps to identify specific mutations that are causative of microspherophakia, enabling diagnosis confirmation and evaluation of disease course. In moderate forms mutations in LTBP2 are the most common, while FBN1 mutations are associated with Weill-Marchesani syndrome.
Pharmacological Interventions
In this particular case, the pharmacological interventions implemented in response to the microspherophakia seeks to treat its complications, primarily the glaucoma and the myopia. The beta-blockers, the prostaglandin analogues and the carbonic anhydrase inhibitors constitute the triad of standard antiglaucoma medication utilized during secondary glaucomas in conjunction with the control of intraocular pressure.
Gene Therapy Approaches
Efforts to study microspherophakia through gene therapy are still at the beginning stage. For example, work is in progress on CRISPR-Cas9 'scissors' that are molecules to reverse the mutations of the LTBP2 and ADAMTS10 genes. There are no human studies yet for microspherophakia, but some preclinical studies are underway.
Protheragen is committed to the development of diagnostic and therapeutic solutions for microspherophakia. We carefully plan diagnostic and therapeutic approaches and always work towards developing new methods and tools.
Protheragen provides specialized target identification and validation services to help clients identify novel therapeutic targets for MSP, leveraging advanced genetic, molecular, and cellular techniques to unravel the complex pathophysiology of the disease. Our services include whole-exome sequencing (WES), homozygosity mapping, and transcriptomic and proteomic profiling of MSP-relevant tissues (such as lens, ciliary processes, and trabecular meshwork) to identify dysregulated genes, proteins, and signaling pathways associated with zonular hypoplasia, lens abnormalities, and disease progression. We validate potential targets using in vitro models, including primary lens epithelial cell cultures, induced pluripotent stem cell (iPSC)-derived ocular cells, and 3D organoids, assessing target expression, function, and relevance to MSP pathology.
Protheragen develops and characterizes validated preclinical models of MSP to support efficacy and safety testing of therapeutic candidates, addressing the lack of standardized models for this rare disease. Our model development services include both in vitro and in vivo models, each designed to recapitulate key MSP phenotypes and pathophysiological features. In vitro models include 2D primary lens epithelial cell cultures, iPSC-derived lens organoids, and 3D microphysiological systems (MPS) that mimic the ocular microenvironment, allowing for the study of lens development, zonular fiber formation, and drug-induced changes in cellular function. These in vitro models are validated using molecular and imaging techniques to confirm the expression of MSP-related markers (e.g., LTBP2, WDR8) and the presence of abnormal lens morphology.
Protheragen offers comprehensive lead optimization and preclinical efficacy evaluation services to help clients advance MSP therapeutic candidates, including small molecules, biologics, gene therapies, and targeted delivery systems. Our lead optimization services focus on improving the potency, selectivity, solubility, and pharmacokinetic properties of lead compounds, using in vitro assays to assess target binding, cellular activity, and toxicity, and in vivo PK studies to evaluate absorption, distribution, metabolism, and excretion (ADME) in relevant animal models.
Protheragen provides rigorous preclinical safety and toxicology evaluation services to ensure that MSP therapeutic candidates are safe for advancement to clinical trials, with a focus on ocular and systemic toxicity. Our safety evaluation services include in vitro toxicity assays (e.g., cytotoxicity, genotoxicity, phototoxicity) using ocular cell lines (e.g., lens epithelial cells, retinal cells) to assess the impact of therapeutic candidates on normal ocular function. We also conduct in vivo toxicology studies in relevant animal models, evaluating acute, subacute, and chronic toxicity, as well as ocular-specific toxic effects such as corneal irritation, lens damage, retinal toxicity, and changes in intraocular pressure.
Protheragen offers specialized PK and PD evaluation services to characterize the pharmacokinetic properties of MSP therapeutic candidates and their relationship to therapeutic efficacy. Our PK studies include the measurement of drug concentrations in plasma, ocular tissues (e.g., lens, aqueous humor, vitreous humor), and other relevant tissues, using sensitive analytical techniques (e.g., LC-MS/MS) to assess absorption, distribution, metabolism, and excretion. We evaluate PK parameters such as Cmax, Tmax, AUC, half-life, and bioavailability, providing clients with critical data to optimize drug formulation and dosing regimens.
The preclinical studies provided by Protheragen are beneficial for the development of therapies for microspherophakia. We conduct systematic preclinical research so that new treatment methodologies are safe and useful before they are instituted in clinical settings. If you are interested in our services, please feel free to contact us.
References
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
As a research service provider, Protehragen offers a comprehensive range of cutting-edge services to advance the development of innovative therapies and unlock the future of rare eye disease therapeutics.
Congenital Ophthalmic Diseases
Hereditary Ophthalmic Diseases
Infectious Ophthalmic Diseases
Copyright © Protheragen. All rights reserved.